Osimertinib Plus Chemo Improves CNS PFS in EGFR+ Advanced NS

Osimertinib plus chemotherapy reduced the risk of central nervous system disease progression or death vs osimertinib alone in patients with locally advanced or metastatic EGFR-positive non–small cell lung cancer who had brain metastases at baseline, according to data from the phase 3 FLAURA2 trial.

Related Keywords

Paris , France General , France , Institut Gustave Roussy , David Planchard , Osimertinib Tagrisso , Astrazeneca , Common Terminology Criteria , Adverse Events , Full Analysis , Non Measurable Lesions , Osimertinib , Egfr Positive Nsclc , Nsclc , Non Small Cell Lung Cancer , Lung Cancer , Tagrisso , Osimertinib Plus Chemo , Flaura2 Trial , Jesmo , Esmo Congress , D , Phd ,